Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.26355/eurrev_202005_21297 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection.
Korean J Intern Med
July 2023
Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, Korea.
Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.
Clin Infect Dis
June 2023
Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Background: With the advent of efficacious oral direct-acting antivirals (DAAs) for hepatitis C virus (HCV), identification of characteristics associated with adherence is critical to treatment success. We examined correlates of sub-optimal adherence to HCV therapy in a single-arm, multinational, clinical trial.
Methods: ACTG A5360 enrolled HCV treatment-naive persons without decompensated cirrhosis from 5 countries.
Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir: how should we choose among these two latest and probably the last regimens?
Hepatol Res
October 2022
Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.
Eur Rev Med Pharmacol Sci
May 2020
Department of Infectious Disease and Emergency Infectious Diseases, D. Cotugno Hospital, Azienda Ospedaliera dei Colli, Naples, Italy.
Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study.
BMC Gastroenterol
March 2020
Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Background: We investigated real-world effectiveness and safety of sofosbuvir and the nonstructural protein 5A inhibitors in the treatment of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, 4, or 6.
Methods: We analyzed data from 1021 patients with HCV infection (506 with genotype 1; 16 with genotype 2; 314 with genotype 3; 13 with genotype 4; 166 with genotype 6) who received 12 to 24 weeks of daclatasvir plus sofosbuvir (n = 767), ledipasvir/sofosbuvir (n = 197), or sofosbuvir/velpatasvir (n = 57), with or without ribavirin in 12 centers across Thailand to estimate sustained virologic response at post-treatment week 12 (SVR12).
Results: Overall, SVR12 rate was 98.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!